- Home
- QXL vs NTRB Comparison
QXL vs NTRB Comparison
Compare QXL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXL | NTRB |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.6M | 72.6M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | QXL | NTRB |
|---|---|---|
| Price | $5.60 | $8.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 62.4K | ★ 67.4K |
| Earning Date | N/A | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $26,941,000.00 | $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $57.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.05 | $2.80 |
| 52 Week High | $7.70 | $8.63 |
Technical Indicators
Market Signals| Indicator | QXL | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 75.77 |
| Support Level | $4.09 | $4.18 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.35 | 0.64 |
| MACD | 0.13 | 0.16 |
| Stochastic Oscillator | 74.87 | 90.70 |
Price Performance
Historical ComparisonAbout QXL Quantum X Labs Inc. Common Stock
Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.